

WHAT IS CLAIMED IS:

1. A method of treating a subject with hot flashes, said method comprising
5 the step of administering to said subject an anti-estrogen agent and/or its
pharmaceutically acceptable salt, hydrate, N-oxide, or any combination
thereof.
2. The method according to claim 1, wherein said anti-estrogen is a
10 selective estrogen receptor modulator (SERM).
3. The method according to claim 1, wherein said anti-estrogen is a
triphenylethylene.
- 15 4. The method according to claim 1, wherein said anti-estrogen is
Toremifene.
5. The method according to claim 1, wherein said administering comprises
intravenously, intraarterially, or intramuscularly injecting to said subject
20 said pharmaceutical composition in liquid form; subcutaneously
implanting in said subject a pellet containing said pharmaceutical
composition; orally administering to said subject said pharmaceutical
composition in a liquid or solid form; or topically applying to the skin
surface of said subject said pharmaceutical composition.
- 25 6. The method according to claim 5 wherein said pharmaceutical
composition is a pellet, a tablet, a capsule, a solution, a suspension, an
emulsion, an elixir, a gel, a cream, a suppository or a parenteral
formulation.
- 30

7. The method according to claim 1, wherein said antiestrogen is administered at a dosage of about 20 mg per day.
8. The method according to claim 1, wherein said antiestrogen is administered at a dosage of about 40 mg per day.
9. The method according to claim 1, wherein said antiestrogen is administered at a dosage of about 60 mg per day.
10. The method according to claim 1, wherein said antiestrogen is administered at a dosage of 80 mg per day.
11. A method of suppressing, inhibiting or reducing the risk of hot flashes, said method comprising the step of administering to said subject an anti-estrogen agent and/or its pharmaceutically acceptable salt, hydrate, N-oxide, or any combination thereof.
12. The method according to claim 11, wherein the anti-estrogen is a selective estrogen receptor modulator (SERM).
13. The method according to claim 11, wherein the anti-estrogen is a triphenylethylene.
14. The method according to claim 11, wherein the anti-estrogen is Toremifene.
15. The method according to claim 11, wherein said administering comprises intravenously, intraarterially, or intramuscularly injecting to said subject said pharmaceutical composition in liquid form; subcutaneously implanting in said subject a pellet containing said

pharmaceutical composition; orally administering to said subject said pharmaceutical composition in a liquid or solid form; or topically applying to the skin surface of said subject said pharmaceutical composition.

5

16. The method according to claim 15, wherein said pharmaceutical composition is a pellet, a tablet, a capsule, a solution, a suspension, an emulsion, an elixir, a gel, a cream, a suppository or a parenteral formulation.

10

17. The method according to claim 11, wherein said antiestrogen is administered at a dosage of about 20 mg per day.

15

18. The method according to claim 11, wherein said antiestrogen is administered at a dosage of about 40 mg per day.

19. The method according to claim 11, wherein said antiestrogen is administered at a dosage of about 60 mg per day.

20

20. The method according to claim 11, wherein said antiestrogen is administered at a dosage of 80 mg per day.

25

21. A method of treating a subject with gynecomastia, said method comprising the step of administering to said subject an anti-estrogen agent and/or its pharmaceutically acceptable salt, hydrate, N-oxide, or any combination thereof.

30

22. The method according to claim 21, wherein said anti-estrogen is a selective estrogen receptor modulator (SERM).

23. The method according to claim 21, wherein said anti-estrogen is a triphenylethylene.
24. The method according to claim 21, wherein said anti-estrogen is
5 Toremifene.
25. The method according to claim 21, wherein said administering comprises intravenously, intraarterially, or intramuscularly injecting to said subject said pharmaceutical composition in liquid form;
10 subcutaneously implanting in said subject a pellet containing said pharmaceutical composition; orally administering to said subject said pharmaceutical composition in a liquid or solid form; or topically applying to the skin surface of said subject said pharmaceutical composition.
- 15 26. The method according to claim 25 wherein said pharmaceutical composition is a pellet, a tablet, a capsule, a solution, a suspension, an emulsion, an elixir, a gel, a cream, a suppository or a parenteral formulation.
- 20 27. The method according to claim 21, wherein said antiestrogen is administered at a dosage of about 20 mg per day.
28. The method according to claim 21, wherein said antiestrogen is
25 administered at a dosage of about 40 mg per day.
29. The method according to claim 21, wherein said antiestrogen is administered at a dosage of about 60 mg per day.
- 30 30. The method according to claim 21, wherein said antiestrogen is

administered at a dosage of 80 mg per day.

- 5 31. A method of suppressing, inhibiting or reducing the risk of gynecomastia, said method comprising the step of administering to said subject an anti-estrogen agent and/or its pharmaceutically acceptable salt, hydrate, N-oxide, or any combination thereof.
- 10 32. The method according to claim 31, wherein the anti-estrogen is a selective estrogen receptor modulator (SERM).
33. The method according to claim 31, wherein the anti-estrogen is a triphenylethylene.
- 15 34. The method according to claim 31, wherein the anti-estrogen is Toremifene.
- 20 35. The method according to claim 31, wherein said administering comprises intravenously, intraarterially, or intramuscularly injecting to said subject said pharmaceutical composition in liquid form; subcutaneously implanting in said subject a pellet containing said pharmaceutical composition; orally administering to said subject said pharmaceutical composition in a liquid or solid form; or topically applying to the skin surface of said subject said pharmaceutical composition.
- 25 36. The method according to claim 35, wherein said pharmaceutical composition is a pellet, a tablet, a capsule, a solution, a suspension, an emulsion, an elixir, a gel, a cream, a suppository or a parenteral formulation.
- 30

37. The method according to claim 31, wherein said antiestrogen is administered at a dosage of about 20 mg per day.
38. The method according to claim 31, wherein said antiestrogen is
5 administered at a dosage of about 40 mg per day.
39. The method according to claim 31, wherein said antiestrogen is administered at a dosage of about 60 mg per day.
- 10 40. The method according to claim 31, wherein said antiestrogen is administered at a dosage of 80 mg per day.